Declining COVID cases, M&A and new products fueled the race to recovery in the Extremities Market
As COVID cases declined in Q221 and patient confidence increased, the Extremities Market was off to the races with a rev-up in deal-making and new product launches. Elective procedure volumes started to make a comeback but were not pedal to the metal and still lagged pre-COVID levels. However, new product launches helped fuel growth in the quarter with the US Extremities Market +43.9% YoY, an increase of +8.2% compared to Q219, reflecting change over pre-COVID market conditions.
Among the many topics covered in detail in our comprehensive Q221 Extremities Market Recap* are: